Effect of Gender on the Pharmacokinetics of ON 123300, A Dual Inhibitor of ARK5 and CDK4/6 for the Treatment of Cancer, in Rats

被引：0
|
作者：
Jennypher Mudunuru
Chen Ren
David R. Taft
Manoj Maniar
机构：
[1] Long Island University,Division of Pharmaceutical Sciences
[2] Onconova Therapeutics,undefined
[3] Inc.,undefined
来源：
European Journal of Drug Metabolism and Pharmacokinetics | 2019年 / 44卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：531 / 538
页数：7
相关论文
共 50 条
  • [41] Cancer and immune cells evolutionary trajectories under treatment with the aromatase inhibitor letrozole and the CDK4/6 inhibitor ribociclib
    Fongard, Marie
    Schmiester, Leonard
    Ghannoum, Salim
    Bjornstad, Marius
    Bosnjak, Tatjana
    Kleivbo, Signe
    Selsas, Knut
    Geisler, Stephanie
    Fjermeros, Kamilla
    Bhargava, Sameer
    Seyedzadeh, Manouchehr
    Buvarp, Unn-Cathrin
    Vuoriluoto, Aino
    Nam Thi Nguyen
    Luders, Torben
    Lambrechts, Diether
    Lyngra, Marianne
    Frigessi, Arnoldo
    Kristensen, Vessela
    Geisler, Jurgen
    Tekpli, Xavier
    CANCER RESEARCH, 2024, 84 (09)
  • [42] The novel potential of palbociclib (CDK4/6 inhibitor) in the treatment of triple-negative breast cancer
    Asano, Yuka
    Kashiwagi, Shinichiro
    Goto, Wataru
    Takahashi, Katsuyuki
    Takashima, Tsutomu
    Noda, Satoru
    Onoda, Naoyoshi
    Tomita, Shuhei
    Hirakawa, Kosei
    Ohira, Masaichi
    CANCER RESEARCH, 2017, 77
  • [43] Breast cancer: CDK4/6 inhibitor plus fulvestrant prolongs survival
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (02)
  • [44] Pfizer's CDK4/6 inhibitor approved for advanced breast cancer
    Chris Morrison
    Nature Biotechnology, 2015, 33 : 323 - 324
  • [45] The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer
    Schoninger, Scott F.
    Blain, Stacy W.
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (01) : 3 - 12
  • [46] Weighted Gene Co-Expression Network Analysis (WGCNA) Identifies Highly Proliferative Myeloma Subgroup Responsive to CDK4/ARK5 Inhibition
    Perumal, Deepak
    Leshchenko, Violetta V.
    Kuo, Pei-Yu
    Jiang, Zewei
    Readhead, Ben
    Eden, Caroline
    Divakar, Sai Krishna Athaluri
    Zhang, Weijia
    Cho, Hearn Jay
    Chari, Ajai
    Reddy, M. V. Ramana
    Reddy, E. Premkumar
    Dudley, Joel
    Jagannath, Sundar
    Parekh, Samir
    BLOOD, 2014, 124 (21)
  • [47] Lysosome-targeted cytocidal effect of CDK4/6 inhibitor abemaciclib
    Hino, Hirotsugu
    Kazama, Hiromi
    Moriya, Shota
    Takano, Naoharu
    Hiramoto, Masaki
    Miyazawa, Keisuke
    CANCER SCIENCE, 2018, 109 : 1026 - 1026
  • [48] Effect of CDK4/6 Inhibitor Palbociclib and Metformin in Ovarian Cancer: Cyclin D as a new Target?
    Tsibulak, I
    Hagenbuchner, J.
    Ausserlechner, M.
    Wieser, V
    Marth, C.
    Zeimet, A. G.
    Fiegl, H.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2020, 80 (04) : 436 - 436
  • [49] CDK4/6 and MAPK-Crosstalk as Opportunity for Cancer Treatment
    Scheiblecker, Lisa
    Kollmann, Karoline
    Sexl, Veronika
    PHARMACEUTICALS, 2020, 13 (12) : 1 - 26
  • [50] Utilizing genome-informed modeling to assess CDK4/6 inhibitor response in breast cancer patients, simulate clinical trials, and result in novel CDK4/6 inhibitor treatment for chordoma patients
    Yang, Mei
    Liu, Yuhan
    Hsueh, Yi-Ching
    Zhang, Qiangzu
    Fan, Yanhui
    Xu, Juntao
    Huang, Min
    Li, Xu
    Chen, Su
    Yang, Jianfei
    Niu, Gang
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
12345